ORTIKOS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORTIKOS (ORTIKOS).
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
| Metabolism | Primarily metabolized by cytochrome P450 (CYP) 3A4, with minor contributions from CYP3A5 and amide hydrolysis. |
| Excretion | Renal (70% unchanged), biliary/fecal (30% as metabolites) |
| Half-life | Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.8 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral: 60% (first-pass effect reduces from 80% absorbed) |
| Onset of Action | Oral: 1-2 hours; IV: 5-10 minutes |
| Duration of Action | Oral: 8-12 hours; IV: 6-8 hours |
| Molecular Weight | 556.53 |
2 mg orally three times daily (total daily dose 6 mg).
| Dosage form | CAPSULE, DELAYED RELEASE |
| Renal impairment | No adjustment required for GFR ≥30 mL/min; contraindicated if GFR <30 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 2 mg twice daily; Child-Pugh C: contraindicated. |
| Pediatric use | Not approved for use in pediatric patients; no established dosing. |
| Geriatric use | Initiate at 2 mg twice daily, titrate cautiously; monitor for adverse effects due to age-related decline in renal function. |
| 1st trimester | Avoid due to teratogenic risk (animal studies show fetal malformations). |
| 2nd trimester | Avoid due to potential fetal harm (limited human data). |
| 3rd trimester | Avoid during labor (may cause uterine atony and postpartum hemorrhage). |
Clinical note
Comprehensive clinical and safety monograph for ORTIKOS (ORTIKOS).
| Placental transfer | Crosses placenta extensively (animal studies show fetal plasma levels >50% maternal levels). |
| Breastfeeding | Excreted in breast milk; potential for serious adverse reactions in nursing infants. Discontinue breastfeeding or discontinue drug, considering importance of drug to mother. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to ortikosPregnancyBreastfeedingSevere hepatic impairment (Child-Pugh C)
| Precautions | Hemorrhage: Fatal bleeding events have occurred. Monitor for signs of bleeding; consider benefit-risk in patients requiring antiplatelet or anticoagulant therapy., Infections: Serious (including fatal) infections have occurred. Monitor for signs and symptoms of infection., Cytopenias: Grade 3 or 4 cytopenias including neutropenia, anemia, and thrombocytopenia have occurred. Monitor complete blood counts periodically., Second primary malignancies: Including skin cancers and other solid tumors have been reported., Cardiac arrhythmias: Atrial fibrillation and flutter have occurred; monitor for arrhythmias and manage appropriately. |
| Food/Dietary | Avoid grapefruit and grapefruit juice during treatment as they may increase systemic exposure. Limit sodium intake if fluid retention occurs. No other significant food interactions reported. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | ORTIKOS is contraindicated in pregnancy. Teratogenic effects include increased risk of cardiovascular malformations (e.g., septal defects) and neural tube defects if used during the first trimester. In the second and third trimesters, exposure may cause fetal growth restriction, oligohydramnios, renal dysfunction, and premature closure of the ductus arteriosus. High risk of fetal nephrotoxicity and oligohydramnios in later trimesters. |
| Fetal Monitoring | For inadvertent exposure in pregnancy, monitor fetal ultrasound for growth, amniotic fluid volume, cardiac anatomy, and renal structure. Monitor maternal blood pressure, renal function (serum creatinine, BUN, urinalysis), and liver function tests (ALT, AST) monthly. Perform fetal echocardiography at 18-22 weeks gestation. Monitor for signs of ductus arteriosus constriction after 28 weeks. |
| Fertility Effects | Preclinical studies show reversible impairment of spermatogenesis in males. In females, may disrupt ovarian cyclicity and reduce ovulation. No clinical data on human fertility; advise to avoid pregnancy during treatment and for 3 months after therapy. |
| Clinical Pearls | ORTIKOS (triamcinolone acetonide) is a synthetic corticosteroid used for intralesional or intra-articular injection. Avoid injection into infected joints or unstable joints. Post-injection flare may occur; consider using a smaller dose for repeat injections. Do not use in patients with systemic fungal infections or known hypersensitivity. Monitor for adrenal suppression with prolonged use. Use the lowest effective dose and shortest duration. |
| Patient Advice | You may experience temporary pain or swelling at the injection site; apply ice if needed. · Avoid strenuous activity or excessive use of the injected joint for 24-48 hours. · Report any signs of infection (redness, warmth, fever) or allergic reaction (rash, difficulty breathing). · Long-term use may increase risk of osteoporosis or diabetes; follow up with your doctor regularly. · Do not stop other medications unless advised by your doctor. |